Prediction of PsA in PSO pts: does it work? First predictive model using mainly clinical data and labs extracted from primary care Performs well in the cohort it was trained w/ but not in validation cohort. Often an issue with prediction models! Needs more granularity than https://t.co/5cVgqfd4fX

‼️Diagnosis of axSpA is clinical -MRI is a tool but still has a lot of limitations. -Improve reports by directly communicating with radiology and be specific on pt clinical info. -Unified algorithms are needed to apply AI in dx of SIJ inflammation on MRI. #EULAR2025 @RheumNow https://t.co/9GR6FsgIcL

Is #PDE5i protective in development of #SSc #ILD? Maybe 444 w ILD of >4000 #EUSTAR Pts over 1 to 2 yrs f/u #immunesuppressive use maybe or not 🤷‍♀️channeling bias Reduction in new #ILD in #scleroderma PDE5i ✅ Immunesuppression ? @RheumNow #EULAR2025 @eular_org #OP0334 https://t.co/6dtLfybkRV

#EULAR2025 Take Home message from Updated EULAR Recommendations @eular_org for #Lupus Nephritis: -Kidney Biopsy vital -Early use of Combination Therapies (HCQ + GC + Immunosuppressant + CNI/Belimumab/Obinutuzumab) -Severe: High dose Cyclo + GC @RheumNow https://t.co/jHFqdT1TLf

🔍MRI lesions in early axSpA vs non axSpA with chronic back pain: -Data from SPACE cohort -n 318 (214 axSpA vs 108 non-axSpA). -Baseline imaging (CR and MRI) and at 2y f/u -Minimal progression on CR in both early axSpA and non-axSpA CBP. -On MRI, significant increase in the https://t.co/m5YOAiFUz1

E3N cohort 78000+ women >30yrs follow up 698 incident RA cases) In non smokers, RA asso w/ -tall at birth HR=1.55 In smokers, RA risk associated w/ -prematurity HR=1.63 -in utero exposure to tobacco HR=1.83 (ns) #EULAR2025 @RheumNow POS0226 https://t.co/xC3k3kiKsZ

PsA asso w/ higher risk of preterm births in women Scandinavian registries 688 PsA pregnancies 8% preterm births vs. 4.5% general population OR 1.8 16.4% if bDMARD combination OR 4 3.1% if bDMARD monotherapy OR 0.7 bDMARDs combo probably a surrogate of high disease activity

Difficult-to-Manage AxSpA: Global Prevalence and Associated Factors The concept of D2M axSpA is a recent development, with the first expert consensus definition published by the Assessment of SpondyloArthritis International Society (ASAS) earlier this year. https://t.co/KmfJvAtwp0

RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty.

Live Daily Eular 2025 Recap Day 2 https://t.co/78NYTcFPG6